Looking for fibromyalgia patients for a new LUMC cannabis study
The Leiden University Medical Center (LUMC) is looking for fibromyalgia patients who wish to participate in a new study into the effects of medicinal cannabis on the medication oxycodon. Patients may register through a special website of the Anaesthesiology Department. Lead researcher Professor Albert Dahan aims to demonstrate that medicinal cannabis in combination with the opiate product oxycodon may have added value in pain relief.
The study will use the cannabis product Bediol®, which contains cannabinoids THC (6.3%) and CBD (8% CBD). There will be three study groups – one group is only given oxycodon, a painkiller based on opium; the second Bediol® in combination with oxycodon; and the third group just Bediol®. The research is carried out by the Anaesthesiology Department and is partly financed by Bedrocan.
Co-medication with Bediol®
The main purpose of the study is to assess whether co-medication with Bediol® reduces the side effects of oxycodon in patients with chronic pain. The study will run for several years. According to the Professor it will be a complex study, because the patients may determine the dose they take. “We will give a maximum, but within that limit patients may determine what they use.” Furthermore, the study takes place in patients’ homes. They will be given a vaporiser that can be used to take the cannabis. “This set-up will definitely succeed, because our researcher will be in continuous contact with the patients.”
“Even in a country like America, where a form of cannabis is legalised in most States, pain specialists do not know how to prescribe or dose medicinal cannabis. I know I cannot make any recommendations on the basis of this experimental study, but I can set them on their way.”
If you are interested in participating in the LUMC study, you can register with the online form on the Dutch website Samen tegen Pijn.
Subscribe to our newsletter
Stay informed with our latest updates by subscribing to our newsletter for exclusive news and compelling content. Rest assured, we prioritize the integrity of your inbox, delivering quality over quantity, with newsletters dispatched judiciously.